This stock is no longer traded. It was delisted on July 9, 2026. Prices stop on that date; discussion is still counted.
Generated by AI
Aditxt Inc. is a biotechnology company focused on discovering, developing, and deploying health innovations that center on the human immune system and advanced diagnostics. The company concentrates on technologies that monitor and modulate immune responses, aiming to better characterize immune status and support more targeted medical interventions. Aditxt’s current portfolio spans several specialized programs and subsidiaries. Adimune develops immune modulation approaches intended to address conditions such as transplant rejection, autoimmune disorders, and allergies. Pearsanta offers personalized laboratory testing, including early cancer detection and other diagnostic services supported by a certified clinical lab infrastructure. Additional programs, such as those under Adivir or related diagnostic initiatives, target infectious diseases and neurological conditions through advanced testing and analytical platforms. Headquartered in Mountain View, California and founded in 2017, Aditxt Inc. operates at the intersection of biotechnology, diagnostics, and immune health, serving healthcare providers, researchers, and diagnostic markets that rely on precise immune and disease profiling.
Website2569 Wyandotte Street
Mountain View, CA, 94043
United States
Summary of Aug 7's posts. Generated by AI.
Summary of Jul 9's posts. Generated by AI.
Summary of Jun 24's posts. Generated by AI.
Summary of Aug 7's posts. Generated by AI.
Investors talking about ADTX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.